Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Materno-fetal hyperoxygenation for underdeveloped fetal left ventricle structures
2022-000608-36Phase 3Active
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxygen in hypoplastic left heart syndrome (HLHS) and Cardiovascular Malformation (CVM) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Primary efficacy endpoint. Started Mar 2022; status: active.
02
Drugs
oxygen
03
Conditions
hypoplastic left heart syndrome (HLHS)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2022-000608-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000608-36.